|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Protects Renal Tubular Cells from Doxorubicin-Induced ApoptosisDepartment of Internal Medicine, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan (C.-C.H., Y.-H.H., Y.-M.S., T.-H.C., T.-H.C., C.-H.C.); Graduate Institute of Pharmacology & Toxicology and Department of Medicine, Tzu Chi University, Hualien, Taiwan (H.L., C.-F.C., T.-H.Chiu); Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (H.L., C.-F.C., H.-H.H., Y.-C.C.); and Department of Pediatrics, Tzu Chi General Hospital, Taipei Branch, Taipei, Taiwan (C.-F.C.)
Peroxisome proliferator-activated receptor-
(PPAR-
) is a transcription factor and has been reported to inhibit cisplatin-mediated proximal tubule cell death. In addition, doxorubicin (Adriamycin)-induced nephrosis in rats is a commonly used experimental model for pharmacological studies of human chronic renal diseases. In this study, we investigated the protective effect of PPAR-
on doxorubicin-induced apoptosis and its detailed mechanism in NRK-52E cells and animal models. The mRNA level of PPAR-
was found to be reduced by doxorubicin treatment in NRK-52E cells. PPAR-
overexpression in NRK-52E cells significantly inhibited doxorubicin-induced apoptosis and the quantity of cleaved caspase-3. Endogenous prostacyclin (PGI2) augmentation, which has been reported to protect NRK-52E cells from doxorubicin-induced apoptosis, induced the translocation and activation of PPAR-
. The transformation of PPAR-
short interfering RNA was applied to silence the PPAR-
gene, which abolished the protective effect of PGI2 augmentation in doxorubicin-treated cells. To confirm the protective role of PPAR-
in vivo, PPAR-
activator docosahexaenoic acid (DHA) was administered to doxorubicin-treated mice, and it has been shown to significantly reduce the doxorubicin-induced apoptotic cells in renal cortex. However, this protective effect of DHA did not exist in PPAR-
-deficient mice. In NRK-52E cells, the overexpression of PPAR-
elevated the activity of catalase and superoxide dismutase and inhibited doxorubicin-induced reactive oxygen species (ROS). PPAR-
overexpression also inhibited the doxorubicin-induced activity of nuclear factor-
B (NF-
B), which was associated with the interaction between PPAR-
and NF-
B p65 subunit as revealed in immunoprecipitation assays. Therefore, PPAR-
is capable of inhibiting doxorubicin-induced ROS and NF-
B activity and protecting NRK-52E cells from doxorubicin-induced apoptosis.
Address correspondence to: Dr. Cheng-Hsien Chen, Nephrology Division, Department of Internal Medicine, Taipei Medical University-Wan Fang Hospital, No 111, Sing-Lung Road, Sec. 3, Wen-Shan District, Taipei City 116, Taiwan. E-mail: hippy{at}tmu.edu.tw
This article has been cited by other articles:
![]() |
H.-H. Chen, Y.-M. Sue, C.-H. Chen, Y.-H. Hsu, C.-C. Hou, C.-Y. Cheng, S.-L. Lin, W.-L. Tsai, T.-W. Chen, and T.-H. Chen Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells Nephrol. Dial. Transplant., June 2, 2009; (2009) gfp258v1. [Abstract] [Full Text] [PDF] |
||||